

Mechanisms of arterial calcifications and consequences for cardiovascular function

G rard M. London¹

¹INSERM U970 Paris, and Nephrology Department Manh s Hospital, Fleury-M rogis, France

Cardiovascular complications are the leading cause of mortality in chronic (CKD) and end-stage renal disease (ESRD). The risk of developing cardiovascular complications is associated with changes in the structure and function of the arterial system, which are in many aspects similar to those occurring with aging. The presence of traditional risk factors does not fully explain the extension and severity of arterial disease. Therefore, other factors associated with CKD and ESRD must also be involved. Arterial calcification (AC) is a common complication of CKD and ESRD, and the extent of AC in general population as well as in patients with CKD is predictive of subsequent cardiovascular mortality beyond established conventional risk factors. AC is an active process similar to bone formation that implicates a variety of proteins involved in bone and mineral metabolism and is considered part of a systemic dysfunction defined as CKD-associated mineral and bone disorder (CKD-MBD).

Kidney International Supplements (2013) **3**, 442–445;
doi:10.1038/kisup.2013.92

KEYWORDS: aging; arteriosclerosis; arterial calcifications; arterial stiffness; chronic renal disease

Premature vascular aging and arterial stiffening are observed with progression of chronic kidney disease (CKD) and in end-stage renal disease (ESRD).¹ Damage of large arteries is a major contributory factor to cardiovascular complications, and a leading cause of mortality in CKD including ESRD.^{2,3} Arterial stiffening in such patients is of multifactorial origin, with extensive arterial calcifications (ACs) representing a major covariate.^{4–6} ACs are predictive of cardiovascular mortality beyond established conventional risk factors.^{7,8} ACs are largely contributing to myocardial ischemia, cardiac hypertrophy, and microvascular disease in brain and kidney.^{9,10}

MECHANISMS OF AC

Long time considered a passive process associated with cellular aging and death, and high extracellular fluid calcium–phosphate concentrations, the results of many recent studies have indicated that cardiovascular calcifications are an active process, in many aspects similar to embryonic bone formation, which is regulated by a variety of genes and proteins implicated in mineral and bone metabolism. This process involves differentiation of contractile vascular smooth muscle cells (VSMCs), and pericytes into distinct, ‘osteoblast-like’ cells with a secretory phenotype. VSMC synthesize bone-associated proteins, including alkaline phosphatase, osteocalcin, osteopontin, and a coat of collagen-rich extracellular matrix, via the formation of matrix vesicles, nodules, and apoptotic bodies, which serve as initiation sites for apatite nanocrystal deposition (but also with bone formation and real ossification).^{11–16} Clinical and experimental data show that this process can be triggered by many factors including dyslipidemia,¹⁷ oxidative stress,¹⁸ advanced glycation end-products and hyperglycemia,¹⁹ hyperphosphatemia,²⁰ increased serum aldosterone levels,²¹ and age-associated cellular senescence.^{22–24} These risk factors have in common that they all converge to a final pathway, that is, inflammation and nuclear factor (NF)- κ B activation.^{25–28} Molecular imaging *in vivo* has demonstrated inflammation-associated osteogenesis in early-stages of atherosclerosis,²⁹ confirming the role of inflammation in triggering the metabolic cascade leading to the transformation of VSMC into an osteogenic phenotype. Macrophage activation releases proinflammatory cytokines (such as interleukin-6 and tumor necrosis factor- α), and proteolytic enzymes (matrix metalloproteinase-2, matrix metalloproteinase-9,

Correspondence: G rard M. London, INSERM U970, Paris, and H pital Manh s, 8, rue Roger Clavier, 91712 Fleury-M rogis, France.
E-mail: glondon@club-internet.fr

and cathepsin S) whose release is associated with osteochondrocytic VSMC transdifferentiation.^{29,30} Interleukin-6 and tumor necrosis factor- α are the first steps for the activation of BMP2:BMP4 and Msx2, which promotes calcification by activating paracrine Wnt signals and nuclear activation and localization of β -catenin, an indispensable coregulator of expression of Runx2, osterix, and Sox9, which are all transcription factors associated with the osteochondrogenic phenotype conversion of VSMC and pericytes.^{30–32} The second aspect of inflammation-related calcification is the proteolytic activation of elastolysis and degradation of extracellular matrix. The fragmentation of elastic lamellae and release of biologically active elastin-derived peptides also promote VSMC dedifferentiation and calcium deposition.^{29,33}

Aging is the most typical condition associated with the development of vascular calcifications. VSMC senescence is associated with the switch to a secretory phenotype (senescence-associated secretory phenotype) that initiates osteoblastic transition with calcifications and artery-wall remodeling.^{22–24} Senescence-associated secretory phenotype is linked to low-grade arterial inflammation with increased NF- κ B activation.³⁴ NF- κ B activity, inflammation, and excessive production of reactive oxygen species are associated with several features of the progeroid syndrome such as accumulation of prelamin A,³⁵ low telomerase activity and telomere shortening,³⁶ and DNA damage,^{24,35} all conditions being associated with the development of an osteogenic program and AC.

In vitro, calcium and phosphate promote both synergistically and independently VSMC calcification.³⁷ Recent findings indicate that hyperphosphatemia, through activation of mitochondrial respiration, stimulates the production of reactive oxygen species with final activation of NF- κ B, enhancing Runx2 (Cbfa1) activation and matrix vesicle release and promoting the differentiation of mesenchymal cells into osteoblastic lineage.³⁸

In presence of normal serum, VSMC do not calcify. Serum inhibits spontaneous calcium and phosphate precipitation in solution,³⁹ indicating that systemic calcification inhibitors are present in the serum and also in VSMC, which constitutively express potent local or systemic inhibitors of calcification,⁴⁰ such as matrix GLA protein,⁴¹ which may limit AC by binding to bone morphogenic proteins.⁴² Osteopontin and osteoprotegerin are potent inhibitors of AC *in vivo*, and inactivation of their genes enhances the calcification process.⁴³ Fetuin-A (AHSG or α_2 -HS glycoprotein) is a potent circulating AC inhibitor that is abundant in plasma.⁴⁴ Pyrophosphate is another potent inhibitor. *In vitro*, phosphate-stimulated apatite production can be completely prevented by adding pyrophosphates.⁴⁵

In CKD and ESRD patients, the relationships between AC and changes in phosphate and calcium homeostasis are associated with disruption of endocrine and humoral pathways, including parathyroid hormone (PTH), calcitriol, and the fibroblast growth factor-23—Klotho—vitamin D axis. The increase in bone resorption observed in CKD patients with

secondary hyperparathyroidism is frequently associated with AC. Excessive phosphate and calcium efflux from bone probably has an important role. The direct intervention of PTH is less clear. Chronically elevated PTH upregulates RANKL, downregulates OPG gene expression, and raises the RANKL/OPG ratio.⁴⁶ However, intermittent increases in serum PTH exert an anabolic action on bone, and intermittent PTH administration has been shown to prevent AC.⁴⁷ Low Klotho expression and resistance to the phosphaturic effect of fibroblast growth factor-23 are also associated with AC.^{20,48–50}

CLINICAL IMPACT OF ACS

Both intima and media calcifications are associated with increased morbidity and mortality,⁷ but they alter arterial functions by different pathological mechanisms.¹ Intima plaque calcification occurs in the context of common atherosclerosis.² Intima calcification induces arterial dysfunction resulting from the narrowing of the arterial lumen with ischemia affecting the tissues and organs downstream.⁹ As calcification advances with the progression of atherosclerosis, it is uncertain whether the calcification itself represents a risk factor or whether it is only a surrogate marker of plaque burden and disease extension. Acute coronary events and myocardial infarction are more related to the biomechanical stability of atherosclerotic plaques and rupture of the fibrous cap of the plaque. Although a higher coronary AC score is associated with a poorer cardiovascular prognosis, the influence of calcification on plaque stability is controversial. The results of several studies indicate that AC does not increase plaque vulnerability, which seems more attributable to a large lipid pool, thin fibrous cap, and intensity of local inflammation.^{51–53}

Media calcification (Mönckeberg's sclerosis or media calcinosis) is characterized by diffuse mineral deposits within the arterial tunica media. Media calcification is concentric, not extending into arterial lumen in its typical pure form and is associated with abnormal cushioning function of blood vessels (arteriosclerosis—arterial hardening) by promoting arterial stiffness.⁵ The first, principal consequence of arterial stiffening is increased systolic pressure, resulting in elevated cardiac afterload and left ventricular hypertrophy. The second consequence is decreased diastolic pressure and impaired coronary perfusion.⁹ As the two forms of AC are frequently associated in patients with CKD abnormalities of conduit and cushioning function are often associated as well.

MANAGEMENT AND PREVENTION

Several experimental studies have shown that the development of AC calcification can be prevented or delayed by several interventions such as treatment with pyrophosphates,⁵⁴ inhibition of receptor activator of NF- κ B,⁵⁵ treatment with bisphosphonates,⁵⁶ estrogens,⁵⁷ cinacalcet,⁵⁸ angiotensin-converting enzyme inhibitors,⁵⁹ and mineralocorticoid receptor antagonists,⁶⁰ and inhibition of bone morphogenic proteins signaling.⁶¹

Regression of AC is rarely observed in humans; therefore, the primary goal is prevention and stabilization of existing calcifications. As intimal AC are related to atherosclerosis, the general approach is nonspecific, as advocated for patients with atherosclerosis: control of blood lipids (but no evidence of a benefit with statins), use of aspirin, treatment of obesity and hypertension, increase in physical activity, cessation of smoking, and optimal control of diabetes. More specific preventive measures for patients with CKD and ESRD include controlling serum calcium and phosphate levels, thereby avoiding hypercalcemia and hyperphosphatemia. Prevention of hyperphosphatemia is based on the diet, increased dialysis efficiency and the prescription of phosphate binders, with the preference for non-calcium-containing binders. Calcium-containing phosphate binders should be avoided or prescribed carefully in patients with permanently low PTH, presence of extensive ACs (old patients), and hypercalcemia. Hypercalcemia and calcium overload are associated with the progression of AC,⁶² oversuppression of PTH, and adynamic bone disease. Oversuppression of PTH and adynamic bone disease are frequently associated with AC⁶³ and should be avoided. Positive calcium balance could be induced by high dialysate calcium concentrations, pharmacological doses of active vitamin D, and calcium-containing phosphate binders. Severe secondary hyperparathyroidism is associated with AC and bone resorption-associated calcium and phosphates release, with hypercalcemia and hyperphosphatemia. In these conditions, the prescription of cinacalcet seems the preferable pharmacological treatment.⁶⁴ Some endogenous calcification inhibitors such as matrix GLA protein are vitamin K dependent. Dialysis patients have vitamin K deficiency and increased levels of inactive dephosphorylated-uncarboxylated matrix GLA protein, which could be reduced by daily vitamin K2 supplementations.^{65,66} The efficiency of vitamin K2 supplementation on AC is under study. Considering these interrelationships, the benefit of warfarin prescription in ESRD patients should be carefully weighed against potential risk.

In conclusion, AC is an active process associated with phenotype transition of VSMCs to osteoblast-like cells. This transition is associated with disrupted balance between factors inducing calcifications and those preventing it. The principal disorders associated with development of vascular calcifications in CKD/ESRD are phosphorus retention in association with positive calcium balance, and decreased activity of factors preventing calcification process.

ACKNOWLEDGMENTS

This supplement was supported by a grant from the 58th Annual Meeting of the Japanese Society for Dialysis Therapy.

DISCLOSURE

GML has received consulting and lecture fees from Amgen and Bayer, and has received consulting fees from Servier.

REFERENCES

- Briet M, Boutouyrie P, Laurent S *et al*. Arterial stiffness and pulse pressure in CKD and ESRD. *Kidney Int* 2012; **82**: 383–400.
- London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. *Kidney Int* 1997; **51**: 1678–1695.
- Blacher J, Guérin AP, Pannier B *et al*. Impact of aortic stiffness on survival in end-stage renal disease. *Circulation* 1999; **99**: 2434–2439.
- Goodman WG, Goldin J, Kuizon BD *et al*. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *New Engl J Med* 2000; **342**: 1478–1483.
- Guérin AP, London GM, Marchais SJ *et al*. Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant* 2000; **15**: 1014–1021.
- Shroff RC, McNair R, Figg N *et al*. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. *Circulation* 2008; **118**: 1748–1757.
- Wilson PWF, Kauppila LI, O'Donnell CJ *et al*. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. *Circulation* 2001; **103**: 1529–1534.
- London GM, Guérin AP, Marchais SJ *et al*. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 2003; **18**: 1731–1740.
- O'Rourke MF. Mechanical principles in arterial disease. *Hypertension* 1995; **26**: 2–9.
- O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. *Hypertension* 2005; **46**: 200–204.
- Demer LL, Tintut Y. Vascular calcification: pathobiology of multifaceted disease. *Circulation* 2008; **117**: 2938–2948.
- Schoppet M, Shroff RC, Hofbauer LC *et al*. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? *Kidney Int* 2008; **73**: 384–390.
- Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification. Lessons learned from the aorta. *Arterioscler Thromb Vasc Biol* 2006; **26**: 1423–1430.
- Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. *Nat Rev Cardiol* 2010; **7**: 528–536.
- Neven E, De Schutter TM, De Broe ME *et al*. Cell biological and physicochemical aspects of arterial calcification. *Kidney Int* 2011; **79**: 1166–1177.
- Reynolds JL, Joannides AJ, Skepper JN *et al*. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. *J Am Soc Nephrol* 2004; **15**: 2857–2867.
- Demer L, Tintut Y. The role of lipid oxidation products and receptor activator of nuclear factor- κ B signaling in atherosclerotic calcification. *Circ Res* 2011; **108**: 1482–1493.
- Mody N, Parhami F, Sarafian TA *et al*. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. *Free Radic Biol Med* 2001; **31**: 509–519.
- Tanikawa T, Okaya Y, Tanikawa R *et al*. Advanced glycation endproducts induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK and upregulation of Runx2. *J Vasc Res* 2009; **46**: 572–580.
- Stubbs JR, Liu S, Tang W *et al*. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. *J Am Soc Nephrol* 2007; **18**: 2116–2124.
- Jaffe IZ, Tintut Y, Newfell BG *et al*. Mineralocorticoid receptor activation promotes vascular cell calcification. *Arterioscler Thromb Vasc Biol* 2007; **27**: 799–805.
- Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells. *Exp Gerontol* 2010; **45**: 819–824.
- Nakano-Kurimoto R, Ikeda K, Uraoka M *et al*. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating osteoblastic transition. *Am J Physiol Heart Circ Physiol* 2009; **297**: H1673–H1684.
- Liu Y, Drozdov I, Shroff R *et al*. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence associated secretory phenotype in vascular smooth muscle cells. *Circ Res* 2013; **112**: e99–e109.
- Doherty TM, Asotra K, Fitzpatrick LA *et al*. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. *Proc Natl Acad Sci USA* 2003; **100**: 11201–11206.
- Shao JS, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification. A review and perspective. *Hypertension* 2010; **55**: 579–592.
- Byon CH, Sun Y, Chen J *et al*. Runx2-upregulated receptor activator of nuclear factor κ B ligand in calcifying smooth muscle cells promotes

- migration and osteoclastic differentiation of macrophages. *Arterioscler Thromb Vasc Biol* 2011; **31**: 1387–1396.
28. Panizo S, Cardus A, Encinas M *et al*. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4 dependent pathway. *Circ Res* 2009; **104**: 1041–1048.
 29. Aikawa E, Nahrendorff Mf, Figueiredo J-L *et al*. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging *in vivo*. *Circulation* 2007; **116**: 2841–2850.
 30. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. *Circ Res* 2011; **109**: 564–577.
 31. Shao J-S, Cheng S-L, Joyce M *et al*. Mx2 promotes cardiovascular calcification by activating paracrine Wnt signals. *J Clin Invest* 2005; **115**: 1210–1220.
 32. Al-Aly Z, Shao J-S, Lai C-F *et al*. Aortic Mx2-Wnt calcification cascade is regulated by TNF- α -dependent signals in diabetic Ldlr $-/-$ mice. *Arterioscler thromb Vasc Biol* 2007; **27**: 2589–2596.
 33. Aikawa E, Aikawa M, Libby P *et al*. Arterial and aortic valve calcification abolished by elastolytic cathepsin deficiency in chronic renal disease. *Circulation* 2009; **119**: 1785–1794.
 34. Tistra JS, Robinson AR, Wang L *et al*. NF- κ B inhibition delays DNA damage-induced senescence and aging in mice. *J Clin Invest* 2012; **122**: 2601–2612.
 35. Ragnauth CD, Warren DT, Yiwen Liu Y *et al*. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* 2010; **121**: 2200–2210.
 36. Carrero JJ, Stenvinkel P, Fellström B *et al*. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. *J Intern Med* 2008; **263**: 302–312.
 37. Shanahan C, Crouthamel MH, Kapustin A *et al*. Arterial calcification in chronic kidney disease: key role for calcium and phosphate. *Circ Res* 2011; **109**: 697–711.
 38. Zhao M-M, Xu M-J, Cai Y *et al*. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate induced vascular calcification *in vitro* and *in vivo*. *Kidney Int* 2011; **79**: 1071–1079.
 39. Moe SM, Duan D, Doehle BP *et al*. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. *Kidney Int* 2003; **63**: 1003–1011.
 40. Schoppet M, Shroff RC, Hofbauer LC *et al*. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? *Kidney Int* 2008; **73**: 384–390.
 41. Luo G, Ducy P, McKee MD *et al*. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature* 1997; **386**: 78–81.
 42. Sweatt A, Sane DC, Hutson SM *et al*. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. *J Thromb Haemost* 2003; **1**: 178–185.
 43. Price PA, June HH, Buckley JR *et al*. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. *Arterioscler Thromb Vasc Biol* 2001; **21**: 1610–1616.
 44. Schafer C, Heiss A, Schwarz A *et al*. The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* 2003; **112**: 357–366.
 45. Lomashvili K, Cobbs S, Hennigar RA *et al*. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. *J Am Soc Nephrol* 2004; **15**: 1392–1401.
 46. Huang JC, Sakata T, Pflieger LL *et al*. PTH differentially regulates expression of RANKL and OPG. *J Bone Miner Res* 2004; **19**: 234–244.
 47. Shao JS, Cheng SL, Charlton-Kachigian N *et al*. Teriparatide [human parathyroid hormone-(1–34)] inhibits osteogenic vascular calcification in diabetes low density lipoprotein receptor-deficient mice. *J Biol Chem* 2003; **278**: 50195–50200.
 48. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. *Biol Chem* 2008; **389**: 233–241.
 49. Hu MC, Shi M, Zhang J *et al*. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 124–136.
 50. Lim K, Lu T-S, Molostvov G *et al*. Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. *Circulation* 2012; **125**: 2243–2255.
 51. Huang H, Virmani R, Younis H *et al*. The impact of calcification on the biomechanical stability of atherosclerotic plaques. *Circulation* 2001; **103**: 1051–1056.
 52. Lin TC, Tintut Y, Lyman A *et al*. Mechanical response of a calcified plaque model to fluid shear force. *Ann Biomed Eng* 2006; **34**: 1535–1541.
 53. Kono K, Fujii H, Nakai K *et al*. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. *Kidney Int* 2012; **82**: 344–351.
 54. O'Neil WC, Lomashvili KA, Malluche HH *et al*. Treatment with pyrophosphate inhibits uremic vascular calcification. *Kidney Int* 2011; **79**: 512–517.
 55. Helas S, Goettsch C, Schoppet M *et al*. Inhibition of receptor activator of NF- κ B ligand by denosumab attenuates vascular calcium deposition in mice. *Am J Pathol* 2009; **175**: 473–478.
 56. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. *Kidney Int* 2006; **70**: 1577–1583.
 57. Osako MK, Nakagami H, Koibuchi N *et al*. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. *Circ Res* 2010; **107**: 466–475.
 58. Kawata T, Nagano N, Obi M *et al*. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. *Kidney Int* 2008; **74**: 1270–1277.
 59. Ng K, Hildreth C, Avolio AP *et al*. Angiotensin-converting enzyme inhibitor limits model of cystic renal disease pulse-wave velocity and aortic calcification in a rat. *Am J Physiol Renal Physiol* 2011; **301**: F959–F966.
 60. Voelkl J, Alesutan L, Leibrock CB *et al*. Spironolactone ameliorates PTT1-dependent vascular osteoinduction in klotho-hypomorphic mice. *J Clin Invest* 2013; **123**: 812–822.
 61. Derwall M, Malhotra R, Lai CS *et al*. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. *Arterioscler Thromb Vasc Biol* 2012; **32**: 613–622.
 62. Chertow GM, Burke SK, Raggi P *et al*. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patient. *Kidney Int* 2002; **62**: 245–252.
 63. London GM, Marchais SJ, Guérin AP *et al*. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. *J Am Soc Nephrol* 2008; **19**: 1827–1835.
 64. The EVOLVE trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med* 2012; **367**: 2482–2494.
 65. Schlieper G, Westenfeld R, Krüger T *et al*. Circulating nonphosphorylated carboxylated matrix GLA protein predicts survival in ESRD. *J Am Soc Nephrol* 2011; **22**: 387–395.
 66. Westenfeld R, Krüger T, Schlieper G *et al*. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialyzed patients: a random trial. *Am J Kidney Dis* 2012; **59**: 186–195.